# A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma

> **NCT07525817** · — · NOT_YET_RECRUITING · sponsor: **Ou Bai, MD/PHD** · enrollment: 40 (estimated)

## Conditions studied

- Mature B-Cell Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib

## Key facts

- **NCT ID:** NCT07525817
- **Lead sponsor:** Ou Bai, MD/PHD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07525817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07525817, "A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07525817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*